VAD chemotherapyโtoxicity and efficacyโi
โ
Dr H. Anderson; J. H. Scarffe; M. Lambert; D. B. Smith; C. C. Chan; G. Chadwick;
๐
Article
๐
2006
๐
John Wiley and Sons
๐
English
โ 529 KB
Thirty-three patients with multiple myeloma (11 untreated, 15 refractory and seven relapsed patients) have received vincristine and adriamycin infusion therapy with oral dexamethasone (VAD). The median number of course received was five. In addition 16 patients with lymphoid malignancy have received